Stimulation of vascularization with VEGF-B

A VEGF-B, vascular technology, applied in cardiovascular system diseases, applications, microorganisms, etc.

Inactive Publication Date: 2005-06-22
LUDWIG INST FOR CANCER RES LTD +1
View PDF6 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] Thus, despite advances in clinical treatment and prevention with existing technologies, inadequate or abnormal post-infarct revascularization remains a major cause of various myocardial deaths, resulting in progressive infarct enlargement and fiber replacement, and eventually heart failure

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Stimulation of vascularization with VEGF-B
  • Stimulation of vascularization with VEGF-B
  • Stimulation of vascularization with VEGF-B

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0063] Example 1: The role of VEGF-B in vascular remodeling after myocardial infarction

[0064] step

[0065] Chronic myocardial ischemia was achieved by ligation of the left anterior descending coronary artery (LAD) of 8-week-old normal and VEGF-B-deficient mice after anesthesia. Published International Application No. WO 98 / 36052 describes VEGF-B deficient mice. Capillary density was the same in wild-type (normal) and knockout (VEGF-B deficient) mice before treatment. Seven days after ligation of the LAD, the infarcted hearts were fixed and collected. Infarcted hearts were sectioned longitudinally (6 m). Hematoxylin and eosin and immunohistochemical staining were performed with thrombomodulin as a marker of endothelial cells and α-actin as a marker of smooth muscle cells. Thrombomodulin antibody was from Dr. Ed Conway, University of Leuven, Belgium. Smooth muscle cell α-actin antibody was obtained commercially (DAKO, X0910, Denmark). Quantinet Q600 image analysis syst...

Embodiment 2

[0073] Example 2: Pro-angiogenic activity of VEGF-B

[0074] According to the method described in Cao et al., Proc.

Embodiment 3

[0075] Example 3: Using VEGF-B to induce angiogenesis

[0076] The ability of VEGF-B to induce angiogenesis in ischemic tissue was determined as described in Witzenbichler et al., Am. J. Pathol. 153:381-394, 1998 .

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention shows that VEGF-B is required for myocardial revascularization after myocardial infarction and discloses methods of promoting or stimulating vascular development, such as angiogenesis and / or arteriogenesis, especially in ischemic mammals.

Description

Background technique [0001] Angiogenesis (i.e., the regeneration of blood vessels (Vasculogenesis)) and angiogenesis (i.e., the generation of new capillaries from pre-existing capillaries (angiogenesis)) are both critical for embryonic development and normal physiological function in adults (Carmeliet, P. ., Mechanisms of angiogenesis and arteriogenesis. Nature Medicine, 2000 6(4) 389-95). Disruption of these processes can lead to early death of the embryo as a result of poor development of the vascular tree and somatic growth. In adults, abnormal angiogenesis can lead to poor wound healing, impaired tissue regeneration in ischemic tissues, impaired cyclic growth of the female reproductive system, and neoplastic development (Carmeliet, P. and R.K. Jain, Tumors and Other Diseases Angiogenesis in. Nature, 2000 407 (6801) 249-57). [0002] The vascular endothelial growth factor (VEGF) family of growth factors is the most important factor involved in physiological and pathologi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7088A61K38/04A61K38/19A61K48/00A61P9/00A61P9/08A61P9/10C12N15/861
CPCA61K38/1825A61K38/1858A61K38/1866A61K48/00A61P9/00A61P9/08A61P9/10C12N15/86C12N2710/10343
Inventor 乌尔夫·埃里克松李旭日彼得·卡尔梅利耶特德西雷·科伦
Owner LUDWIG INST FOR CANCER RES LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap